Be the first person to write a business review for Santa Cruz Biotechnology, Inc.

Savient Pharmaceuticals, Inc. company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey. Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers.

Scios Inc. company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.

Seattle Genetics, Inc. company was founded in 1997 and is headquartered in Bothell, Washington. Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma under a special protocol assessment. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; and SGN-70, a humanized anti-CD70 antibody. In addition, its product candidates in development comprise SGN-75 for CD70-positive hematologic malignancies and solid tumors; AGS-5ADC for solid tumors; and SGN-19A for CD19-positive hematologic malignancies. It has a collaboration agreement with Genentech, Inc. to develop and commercialize Dacetuzumab; with Genentech, Inc., Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., and MedImmune Inc. for the company's antibody-drug conjugates (ADC) technology; and an ADC co-development agreement with Agensys, Inc.

Semafore Pharmaceuticals is signaling its arrival on the oncology drug making scene. The development-stage drug discovery company is targeting the PI3K cell signaling pathways to create anti-cancer drugs. Its PI3K Inhibitors induce the death of cancerous cells in the treatment of tumors and could potentially treat brain, lung, and hematological cancers. Once administered, its lead candidate SF1126 attacks proteins expressed in tumors, but ignores healthy cells. Semafore has brought on a consulting firm to help shepherd SF1126 through its next stage of development.

Senesco Technologies Inc. company was founded in 1964 and is headquartered in New Brunswick, New Jersey. Senesco Technologies, Inc. (Senesco) is a development-stage biotechnology company. The Company along with its wholly owned subsidiary, Senesco, Inc., is engaged in utilizing its eucaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for inhibition in human health applications to develop approaches to treat inflammatory diseases and cancer. In agricultural applications the Company is developing and licensing Factor 5A, DHS and Lipase to enhance the quality and productivity of fruits, flowers, and vegetables and agronomic crops through the control of cell death, referred to herein as senescence, and growth in plants.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.